Abstract
[Display omitted]
•Synthesis and characterization of 17 new 4-aminosalicylic acid derivatives.•In vivo and in vitro testing of anti-inflammatory activity and in vitro antimycobacterial activity.•The compounds have good safety profile; they are neither cytotoxic nor ulcerogenic.•Two new compounds (19 and 20) are proposed as potential lead compounds for the discovery of dual anti-inflammatory and anti-TB drug candidates.•Molecular docking studies disclosed important binding modes with COX-2 and 15-LOX.
In this study, new derivatives of the antitubercular and anti-inflammatory drug, 4-aminosaliclic acids (4-ASA) were synthesized, characterized, and evaluated for these activities. In vivo and in viro evaluation of anti-inflammatory activity revealed that compounds 10, 19 and 20 are the most active with potent cyclooxygenase-2 (COX-2) and 5-lipooxgenase (5-LOX) inhibition and without causing gasric lesions. The minimum inhibitory concentrations (MIC) of the newly synthesized compound were, also, measured against Mycobacterium tuberculosis H37RV. Among the tested compounds 17, 19 and 20 exhibited significant activities against the growth of M. tuberculosis. 20 is the most potent with (MIC 1.04 µM) 2.5 folds more potent than the parent drug 4-ASA. 20 displayed low cytotoxicity against normal cell providing a high therapeutic index. Important structure features were analyzed by docking and structure–activity relationship analysis to give better insights into the structural determinants for predicting the anti-inflammatory and anti-TB activities. Our results indicated that compounds 19 and 20 are potential lead compounds for the discovery of dual anti-inflammatory and anti-TB drug candidates.